ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1453

Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus

Liza Rajasekhar1, Vineetha Shobha2, Meenakshi Ponnana3, Chengappa Kavadichanda4, Ashish J Mathew5, Saumya Ranjan Tripathy6, Manish Rathi7, Parasar Ghosh8, Ranjan Gupta9, Avinash Jain10 and Amita Aggarwal11, 1Nizam's Institute of Medical Sciences, Madhapur, India, 2St. John’s Medical College Hospital, Bangalore, India, 3Nizam's Institute of Medical Sciences, Hyderabad, India, 4JIPMER, Pondicherry, Puducherry, India, 5Rigshospitalet, Copenhagen, Denmark, 6SCB medical college, Cuttack, India, 7PGIMER Chandigarh, Chandigarh, India, 8Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 9All India Institute of Medical Sciences, New Delhi, India, 10SMS Medical College, Lucknow, India, 11Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Infection, Mortality, Myositis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Muscle inflammation in systemic lupus erythematosus (SLE) usually presents as generalised myalgia in the presence of active disease elsewhere and responds well to treatment. There is paucity of data on myositis in lupus. We assessed the frequency and association of myositis in an inception cohort of SLE from India (INSPIRE).

Methods: The INSPIRE database includes patients satisfying the SLICC classification criteria for SLE with disease duration less than 3 years at 10 tertiary care hospitals across India. Myositis was defined by proximal muscle aching/weakness, associated with elevated CPK or LDH or AST or ALT. Other causes/drug induced myopathy or muscle enzyme elevation were excluded. Data on demographics, clinical, lab features, autoantibodies, and disease activity (SLEDAI, BILAG score), damage (SDI) and mortality were retrieved from the electronic database. SLE patients with myositis (cases) were compared with those not having myositis (controls). Difference in means between groups was done using student’s t-test and difference in proportions using the chi-square test. Presence of infection, BILAG category A or B disease in any domain, myositis, gender were used as predictors of mortality using binomial logistic regression.

Results: A total of 2210 patients including 2029 (91.8%) females were enrolled in the study. Mean (SD) age at diagnosis was 28.9±0.79 years. Mean (SD) duration of disease was 16.4±0.45 months. Comorbidities included hypothyroidism (16.4%), hypertension in (8.8%), diabetes mellitus (1.6%). 133 patients died during mean follow-up of 22.4±12.5 months.125 (5.6%) patients had myositis, with myalgia present in 88%. On univariate analysis, cases were younger, with more frequent fever, acute cutaneous lupus, oral ulcers, pleural effusion, leukopenia, thrombocytopenia, lower haemoglobin, complements, and albumin and higher ALT, AST, LDH, CPK. SLEDAI and BILAG scores than controls (Table 1). Antibodies to Ro60 were more frequent in patients with myositis. Twelve cases had muscle damage as assessed by SDI. Patients with myositis had a significantly lower survival (87% vs 94%, p< 0.001, Figure 1). Univariate analysis identified fever, SLEDAI and CPK as the predictors of myositis at p< 0.05. Binomial logistic regression identified infection as a predictor of mortality at p< 0.03.

Conclusion: The prevalence of myositis in an Indian lupus cohort with early, very active disease was 5.6 %. Those with myositis had more active disease elsewhere, had similar damage but lower survival than those without. Myositis was not a predictor of mortality.

Supporting image 1

Survival in patients with Myositis

Supporting image 2


Disclosures: L. Rajasekhar, None; V. Shobha, None; M. Ponnana, None; C. Kavadichanda, None; A. Mathew, None; S. Tripathy, None; M. Rathi, None; P. Ghosh, None; R. Gupta, None; A. Jain, None; A. Aggarwal, None.

To cite this abstract in AMA style:

Rajasekhar L, Shobha V, Ponnana M, Kavadichanda C, Mathew A, Tripathy S, Rathi M, Ghosh P, Gupta R, Jain A, Aggarwal A. Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-associations-of-myositis-in-an-indian-inception-cohort-of-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-associations-of-myositis-in-an-indian-inception-cohort-of-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology